{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:47Z","timestamp":1792712447626,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-158"],"award-info":[{"award-number":["BCRF-158"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["SAC110034"],"award-info":[{"award-number":["SAC110034"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180712"],"award-info":[{"award-number":["RP180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is important to understand how the biology of breast cancer might differ with the burden of disease. Analyzing the expression of cancer-relevant genes with increasing diagnostic stage can provide insight into the changing biology of breast cancer and may also be clinically useful. Here, we evaluated the transcriptional activity according to the stage of breast cancer (American Joint Committee on Cancer, AJCC Stage I to IV) from 1152 patients with hormone receptor-positive HER2-negative breast cancer. Fresh tumor samples were prospectively collected for clinical-translational research with transcriptional profiling. Most transcriptional signatures remained consistent across stage categories, but the significant changes associated with increasing stage were attributed to endocrine escape, decreasing differentiation, increased complexity of signal transduction, and a few metabolic changes. The clinical relevance and implications of these findings are discussed. The expression data from these high-quality samples are a new publicly available resource for researchers.<\/jats:p>","DOI":"10.1038\/s41523-026-00973-6","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:08:02Z","timestamp":1783004882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-related transcriptional changes in HR-positive\/HER2-negative breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"William S. O.","family":"Symmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Andreopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"973_CR1","first-page":"290","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano, A. E. et al. Breast Cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 290\u2013303 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"973_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"973_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky, K. et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385, 2336\u20132347 (2021).","journal-title":"N. Engl. J. Med."},{"key":"973_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717\u2013729 (2016).","journal-title":"N. Engl. J. Med."},{"key":"973_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"973_CR6","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","volume":"24","author":"KR Hess","year":"2006","unstructured":"Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236\u20134244 (2006).","journal-title":"J. Clin. Oncol."},{"key":"973_CR7","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","volume":"28","author":"WF Symmans","year":"2010","unstructured":"Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111\u20134119 (2010).","journal-title":"J. Clin. Oncol."},{"key":"973_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0111-0","volume":"5","author":"BV Sinn","year":"2019","unstructured":"Sinn, B. V. et al. SET(ER\/PR): a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. npj Breast Cancer 5, 16 (2019).","journal-title":"npj Breast Cancer"},{"key":"973_CR9","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jama.2011.593","volume":"305","author":"C Hatzis","year":"2011","unstructured":"Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305, 1873\u20131881 (2011).","journal-title":"JAMA"},{"key":"973_CR10","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1002\/cncr.11435","volume":"97","author":"WF Symmans","year":"2003","unstructured":"Symmans, W. F. et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97, 2960\u20132971 (2003).","journal-title":"Cancer"},{"key":"973_CR11","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos, P. et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 11, 2796\u20132811 (2021).","journal-title":"Cancer Discov."},{"key":"973_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard, F. C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. 393, 569\u2013580 (2025).","journal-title":"N. Engl. J. Med."},{"key":"973_CR13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 23, 1367\u20131377 (2022).","journal-title":"Lancet Oncol."},{"key":"973_CR14","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized Phase III EMERALD trial. J. Clin. Oncol. 40, 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."},{"key":"973_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"973_CR16","doi-asserted-by":"publisher","unstructured":"Sever, R. & Brugge, J. S. Signal transduction in cancer. Cold Spring Harb. Perspect. Med. 5, https:\/\/doi.org\/10.1101\/cshperspect.a006098 (2015).","DOI":"10.1101\/cshperspect.a006098"},{"key":"973_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01328-0","volume":"22","author":"CT van Geelen","year":"2020","unstructured":"van Geelen, C. T. et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res. 22, 91 (2020).","journal-title":"Breast Cancer Res."},{"key":"973_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-017-0015-5","volume":"7","author":"TC Beadnell","year":"2018","unstructured":"Beadnell, T. C. et al. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7, 23 (2018).","journal-title":"Oncogenesis"},{"key":"973_CR19","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1200\/JCO-25-00663","volume":"43","author":"S Wedam","year":"2025","unstructured":"Wedam, S. et al. US Food and Drug Administration Approval Summary: Inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer. J. Clin. Oncol. 43, 3123\u20133131 (2025).","journal-title":"J. Clin. Oncol."},{"key":"973_CR20","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"973_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009734.2012.659294","volume":"117","author":"A J\u00f6gi","year":"2012","unstructured":"J\u00f6gi, A., Vaapil, M., Johansson, M. & P\u00e5hlman, S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups. J. Med. Sci. 117, 217\u2013224 (2012).","journal-title":"Ups. J. Med. Sci."},{"key":"973_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"973_CR23","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1158\/1078-0432.CCR-25-0327","volume":"31","author":"L Gerratana","year":"2025","unstructured":"Gerratana, L. et al. Circulating tumor cell dynamics after CDK4\/6 inhibitor for hormone receptor-positive metastatic breast cancer: a biomarker analysis from the PACE Phase II study. Clin. Cancer Res. 31, 4510\u20134517 (2025).","journal-title":"Clin. Cancer Res."},{"key":"973_CR24","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized Phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41, 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol."},{"key":"973_CR25","doi-asserted-by":"publisher","unstructured":"Mayer, E. et al. Abstract GS3-06: GS3-06 Palbociclib After CDK4\/6i and Endocrine Therapy (PACE): a randomized Phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+\/HER2- metastatic breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.sabcs22-gs3-06 (2023).","DOI":"10.1158\/1538-7445.sabcs22-gs3-06"},{"key":"973_CR26","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","volume":"20","author":"FJ Esteva","year":"2019","unstructured":"Esteva, F. J., Hubbard-Lucey, V. M., Tang, J. & Pusztai, L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20, e175\u2013e186 (2019).","journal-title":"Lancet Oncol."},{"key":"973_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim, S. K. & Cho, S. W. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front. Pharmacol. 13, 868695 (2022).","journal-title":"Front. Pharmacol."},{"key":"973_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32, 169\u2013184.e7 (2017).","journal-title":"Cancer Cell"},{"key":"973_CR29","doi-asserted-by":"publisher","unstructured":"Adapa, S. R. et al. Porphyrin overdrive rewires cancer cell metabolism. Life Sci. Alliance 7, https:\/\/doi.org\/10.26508\/lsa.202302547 (2024).","DOI":"10.26508\/lsa.202302547"},{"key":"973_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381\u2013396 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"973_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi, R. et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature 591, 652\u2013658 (2021).","journal-title":"Nature"},{"key":"973_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DM Gendoo","year":"2016","unstructured":"Gendoo, D. M. et al. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics 32, 1097\u20131099 (2016).","journal-title":"Bioinformatics"},{"key":"973_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s43018-022-00491-x","volume":"4","author":"S Garcia-Recio","year":"2023","unstructured":"Garcia-Recio, S. et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat. Cancer 4, 128\u2013147 (2023).","journal-title":"Nat. Cancer"},{"key":"973_CR34","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/jnci\/djr438","volume":"103","author":"C Hatzis","year":"2011","unstructured":"Hatzis, C. et al. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J. Natl. Cancer Inst. 103, 1871\u20131883 (2011).","journal-title":"J. Natl. Cancer Inst."},{"key":"973_CR35","doi-asserted-by":"publisher","unstructured":"Li, J., Fu, C., Speed, T. P., Wang, W. & Symmans, W. F. Accurate RNA sequencing from formalin-fixed cancer tissue to represent high-quality transcriptome from frozen tissue. JCO Precis. Oncol. 2018, https:\/\/doi.org\/10.1200\/PO.17.00091 (2018).","DOI":"10.1200\/PO.17.00091"},{"key":"973_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/cncy.22679","volume":"131","author":"M Marczyk","year":"2023","unstructured":"Marczyk, M. et al. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. Cancer Cytopathol. 131, 289\u2013299 (2023).","journal-title":"Cancer Cytopathol."},{"key":"973_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jnci\/djr545","volume":"104","author":"B Haibe-Kains","year":"2012","unstructured":"Haibe-Kains, B. et al. A three-gene model to robustly identify breast cancer molecular subtypes. J. Natl. Cancer Inst. 104, 311\u2013325 (2012).","journal-title":"J. Natl. Cancer Inst."},{"key":"973_CR38","unstructured":"R Core Team. R: a language and environment for statistical computing. http:\/\/www.R-project.org\/ (2015)."},{"key":"973_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121 (2015).","journal-title":"Nat. Methods"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00973-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00973-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00973-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:17:46Z","timestamp":1792711066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00973-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00973-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8207456\/v1","asserted-by":"object"}]},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare. Non-competing interests that might be perceived to influence the discussion in this paper were: W.F.S. reports stock and other ownership interests in IONIS Pharmaceuticals, Delphi Diagnostics, and Eiger BioPharmaceuticals; consulting or advisory roles for AstraZeneca; research funding from Pfizer (paid to Institution); Co-inventor, US Patent No. 11,459,617 \u201cTargeted Measure of Transcriptional Activity Related to Hormone Receptors,\u201d issued on October 4, 2022 (applicant proprietor: University of Texas MD Anderson Cancer Center) and licensed to Delphi Diagnostics; and an uncompensated scientific advisor relationship with Delphi Diagnostics. C.F. reports stock in Delphi Diagnostics and co-inventor on US Patent No. 11,459,617. The other authors do not have any relevant non-competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"140"}}